Y-mAbs Therapeutics (YMAB) Competitors

Y-mAbs Therapeutics (NASDAQ:YMAB) and Phibro Animal Health (NASDAQ:PAHC) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, risk, analyst recommendations, institutional ownership, profitability, valuation and earnings.

Which has more volatility & risk, YMAB or PAHC?

Y-mAbs Therapeutics has a beta of 0.54, indicating that its share price is 46% less volatile than the S&P 500. Comparatively, Phibro Animal Health has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500.

Do institutionals and insiders have more ownership in YMAB or PAHC?

70.9% of Y-mAbs Therapeutics shares are held by institutional investors. Comparatively, 99.3% of Phibro Animal Health shares are held by institutional investors. 19.7% of Y-mAbs Therapeutics shares are held by insiders. Comparatively, 50.1% of Phibro Animal Health shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Which has stronger earnings & valuation, YMAB or PAHC?

Phibro Animal Health has higher revenue and earnings than Y-mAbs Therapeutics. Y-mAbs Therapeutics is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Y-mAbs Therapeutics	$87.68M	4.46	-$29.67M	-$0.50	-17.22
Phibro Animal Health	$1.30B	1.14	$48.26M	$1.18	31.00

Does the media prefer YMAB or PAHC?

In the previous week, Phibro Animal Health had 19 more articles in the media than Y-mAbs Therapeutics. MarketBeat recorded 20 mentions for Phibro Animal Health and 1 mentions for Y-mAbs Therapeutics. Phibro Animal Health's average media sentiment score of 0.64 beat Y-mAbs Therapeutics' score of 0.00 indicating that Phibro Animal Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Y-mAbs Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Phibro Animal Health	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Is YMAB or PAHC more profitable?

Phibro Animal Health has a net margin of 3.73% compared to Y-mAbs Therapeutics' net margin of -26.03%. Phibro Animal Health's return on equity of 32.14% beat Y-mAbs Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Y-mAbs Therapeutics	-26.03%	-24.60%	-18.89%
Phibro Animal Health	3.73%	32.14%	6.89%

Do analysts prefer YMAB or PAHC?

Y-mAbs Therapeutics presently has a consensus price target of $9.62, indicating a potential upside of 11.76%. Phibro Animal Health has a consensus price target of $28.40, indicating a potential downside of 22.36%. Given Y-mAbs Therapeutics' higher probable upside, research analysts plainly believe Y-mAbs Therapeutics is more favorable than Phibro Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Y-mAbs Therapeutics	2 Sell rating(s)	8 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
Phibro Animal Health	2 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.13

Summary

Phibro Animal Health beats Y-mAbs Therapeutics on 15 of the 17 factors compared between the two stocks.